Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

147.78 -0.40 (-0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 608,017
Open 150.23
Bid (Size) 137.50 (100)
Ask (Size) 236.24 (200)
Prev. Close 148.18
Today's Range 146.83 - 151.24
52wk Range 57.90 - 160.81
Shares Outstanding 62,577,897
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
From Protagonist Therapeutics
Via ACCESS Newswire

Performance

YTD
+69.5%
+69.5%
1 Month
-6.8%
-6.8%
3 Month
+31.4%
+31.4%
6 Month
+52.7%
+52.7%
1 Year
+153.1%
+153.1%

More News

Read More
News headline image
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment ↗
Via MarketBeat
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
Via The Motley Fool
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth with a Promising Technical Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Passes Minervini Trend Template and High-Growth Screen ↗
Via Chartmill
News headline image
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum ↗
Via Chartmill
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
From Protagonist Therapeutics
Via ACCESS Newswire
News headline image
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
Via ACCESS Newswire
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
Via The Motley Fool
News headline image
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
Via ACCESS Newswire
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
Via ACCESS Newswire
News headline image
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Via ACCESS Newswire

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
The current price of Protagonist Therapeutics, Inc. - Common Stock is 147.78
When was Protagonist Therapeutics, Inc. - Common Stock last traded?
The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 09/14/26 04:00 PM ET
What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 9.25B
How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
Protagonist Therapeutics, Inc. - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.